Next Article in Journal
Anti-Inflammatory Effect of Wogonin on RAW 264.7 Mouse Macrophages Induced with Polyinosinic-Polycytidylic Acid
Next Article in Special Issue
A Highlight of Recent Advances in Aptamer Technology and Its Application
Previous Article in Journal
Efficient Synthesis of Readily Water-Soluble Sulfonic Acid Carbamates
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(4), 6866-6887; doi:10.3390/molecules20046866

Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics

Operational Technologies Corporation, 4100 NW Loop 410, Suite 230, San Antonio, TX 78229, USA
Academic Editor: Jean Jacques Vanden Eynde
Received: 19 March 2015 / Revised: 4 April 2015 / Accepted: 7 April 2015 / Published: 16 April 2015
(This article belongs to the Special Issue Aptamers: Past, Present, and Future)
View Full-Text   |   Download PDF [1435 KB, uploaded 16 April 2015]   |  

Abstract

Despite the great promise of nucleic acid aptamers in the areas of diagnostics and therapeutics for their facile in vitro development, lack of immunogenicity and other desirable properties, few truly successful aptamer-based products exist in the clinical or other markets. Core reasons for these commercial deficiencies probably stem from industrial commitment to antibodies including a huge financial investment in humanized monoclonal antibodies and a general ignorance about aptamers and their performance among the research and development community. Given the early failures of some strong commercial efforts to gain government approval and bring aptamer-based products to market, it may seem that aptamers are doomed to take a backseat to antibodies forever. However, the key advantages of aptamers over antibodies coupled with niche market needs that only aptamers can fill and more recent published data still point to a bright commercial future for aptamers in areas such as infectious disease and cancer diagnostics and therapeutics. As more researchers and entrepreneurs become familiar with aptamers, it seems inevitable that aptamers will at least be considered for expanded roles in diagnostics and therapeutics. This review also examines new aptamer modifications and attempts to predict new aptamer applications that could revolutionize biomedical technology in the future and lead to marketed products. View Full-Text
Keywords: antibody; aptamer; diagnostic; humanized; modified base; multivalent; therapeutic antibody; aptamer; diagnostic; humanized; modified base; multivalent; therapeutic
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bruno, J.G. Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics. Molecules 2015, 20, 6866-6887.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top